Erica Rogers, the CEO of hot medtech IPO Silk Road Medical (NSDQ:SILK), learned an important career lesson back in the 1990s. After more than 10 years at Boston Scientific, Rogers didn’t want to move from the West Coast to Boston to try to rise up through the company even more. As she recently related to Medsider’s […]
Silk Road Medical Inc.
Silk Road Medical ups its stock offering by $31.8 million
Silk Road Medical (NSDQ:SILK) increased a stock offering it registered earlier this week to $191.8 million, according to a regulatory filing. The company’s original registration for $159 million was to fund its transcarotid artery revascularization (TCAR) technology for the treatment of stroke. The Sunnyvale, Calif.-based company is now proposing an offering of 4.8 million shares of its […]
Silk Road Medical proposes $159m stock offering
Silk Road Medical (NSDQ:SILK) has registered a $159 million stock offering to fund its transcarotid artery revascularization (TCAR) technology for the treatment of stroke, according to a regulatory filing. The Sunnyvale, Calif.-based company is proposing an offering of 4.04 million shares of its common stock at a maximum share price of $39.50 each, including 525,000 […]
Silk Road Medical touts results of carotid artery treatment study
A new study shows that transcarotid artery revascularization (TCAR) procedures significantly lowered the odds of composite in-hospital stroke, death and heart attack compared to surgical removal of plaque from the carotid artery, according to Silk Road Medical (NSDQ:SILK). The company is developing a neuroprotection and stent system called Enroute as an aid to TCAR procedures. […]
Silk Road Medical posts mixed-bag Q1
Silk Road Medical (NSDQ:SILK) yesterday posted first quarter earnings that topped sales expectations but missed on loss-per-share consensus on Wall Street. The Sunnyvale, Calif.-based company posted losses of approximately $24.2 million, or $20.12 per share, on sales of approximately $12.8 million for the three months ended March 31, seeing losses grow 346.7% while sales grew 123.7% […]
Silk Road Medical clears $109m in IPO
Silk Road Medical (NSDQ:SILK) said yesterday that it cleared just more than $109 million in its initial public offering, including a fully subscribed underwriters option. The $20-per-share flotation grossed $120 million, Sunnyvale, Calif.-based Silk Road said. The company is developing a neuroprotection and stent system called Enroute as an aid to transcarotid artery revascularization procedures. Silk […]
UPDATE: Silk Road Medical prices $120m IPO
Updated to include comment from CEO Erica Rogers Silk Road Medical late yesterday priced its initial public offering, looking to raise approximately $120 million. The Sunnyvale, Calif.-based company said it plans to float 6 million shares of its common stock at a price of $20 per share. The offering also includes a 30-day underwriters option to […]
Silk Road Medical upsizes IPO
Silk Road Medical today boosted the size of its pending initial public offering to as much as $120 million. When it registered the IPO in March, Silk Road said it could fetch as much as $86 million. But last week the Sunnyvale, Calif.-based company cut the range, saying it planned to float nearly 4.7 million […]
Silk Road Medical sets downsized range for IPO
Silk Road Medical yesterday set the range on its forthcoming initial public offering, which would fetch $75 million at the midpoint. The Sunnyvale, Calif.-based company’s Enroute transcarotid stent and neuroprotection system is designed to treat carotid artery blockages before they cause a stroke. When it registered the IPO earlier this month, Silk Road said it […]
Silk Road registers for $86m IPO
Silk Road Medical has registered for an initial public offering, looking to bring in approximately $86.3 million, according to a recently posted SEC filing. The Sunnyvale, Calif.-based company said that it applied to list its common stock on the NASDAQ exchange using the symbol “SILK,” according to the filing. The company’s flagship product is its […]
Silk Road Medical touts TCAR study data
Silk Road Medical today released results from studies of its transcarotid artery revascularization procedure, touting favorable outcomes in treating patients with carotid artery disease. Data from the studies were presented at the Society for Vascular Surgery 2018 Vascular Annual Meeting in Boston. The transcarotid artery revascularization procedure uses the Sunnyvale, Calif.-based company’s Enroute transcarotid stent […]